표제지
초록
목차
1. 연구 배경 및 목적 10
2. 연구 방법 14
(1) aPL 연관 뇌졸중의 인식 현황 및 임상적 중요성 14
1) 연구 대상 환자 14
2) 자료 수집 14
3) 통계분석방법 15
(2) aPL 연관 뇌졸중의 영상의학적 특징 17
1) 연구 대상 환자 17
2) 자료 수집 17
3) 통계분석방법 19
(3) aPL 연관 뇌졸중의 최적의 치료 전략 20
1) 연구 대상 환자 20
2) 자료 수집 20
3) 통계분석방법 21
3. 연구 결과 22
(1) aPL 연관 뇌졸중의 인식 현황 및 임상적 중요성 22
(2) aPL 연관 뇌졸중의 영상의학적 특징 24
(3) aPL 연관 뇌졸중의 최적의 치료 전략 26
4. 고찰 28
5. 참고 문헌 33
Abstract 77
Table 1. Baseline characteristics according to whether patients received antiphospholipid antibody testing or not 37
Table 2. Binary logistic regression analysis of factors associated with performing aPL testing in patients with acute ischemic stroke 38
Table 3. Binary logistic regression analysis of factors associated with aPL positivity in patients with acute ischemic stroke 39
Table 4. Baseline parameters according to aPL positivity among patients tested for aPL 40
Table 5. Baseline parameters according to aPL positivity among cryptogenic stroke patients tested for aPL 41
Table 6. Comparison of baseline characteristics, profiles associated with aPL tests, and recurrence of ischemic stroke... 42
Table 7. Multivariate odds ratios for performing aPL testing and aPL positivity among patients with acute ischemic stroke, with exclusion of potential sources of false positive aPL results 44
Table 8. Multivariate odds ratios for performing aPL testing and aPL positivity among patients with cryptogenic stroke, with exclusion of potential source 45
Table 9. Clinical and laboratory characteristics of aPL-and AF-stroke patients 46
Table 10. Univariate and multivariate binary logistic regression of the neuroimaging parameters in aPL-stroke 48
Table 11. Baseline clinical characteristics of the APS-stroke, aPL-stroke, and AF-stroke groups 49
Table 12. Imaging characteristics of the APS-stroke, aPL-stroke, and AF-stroke groups 52
Table 13. Baseline characteristics according to secondary preventive antithrombotic drug category for aPL-related stroke 53
Table 14. Baseline characteristics according to dichotomized secondary preventive antithrombotic drug category for aPL-... 55
Table 15. Bivariate analysis for composite outcome event occurrence 57
Table 16. Hazard of clinical outcomes according to secondary preventive antithrombotic drug category for aPL-related stroke 59
Table 17. Hazard of clinical outcomes according to dichotomized secondary preventive antithrombotic drug... 61
Figure 1. Representative examples of the diffusion-weighted imaging lesion pattern 62
Figure 2. Representative example of semiautomated segmentation of infarcted areas on diffusion-weighted imaging 63
Figure 3. Representative examples of patterns of relevant artery occlusion 64
Figure 4. aPL testing rate/positivity according to age and the presence of identified etiology in patients with acute ischemic stroke 65
Figure 5. aPL testing rate/positivity according to age in patients with acute ischemic stroke 66
Figure 6. aPL testing rate/positivity according to age in patients with cryptogenic stroke 67
Figure 7. Neuroimaging features of aPL-and AF-stroke patients 68
Figure 8. Proportion of patients who experienced relevant artery occlusion among aPL-and AF-stroke patients 70
Figure 9. DWI lesion pattern and total lesion volume of aPL-and AF-stroke patients with a multi-territory lesion 71
Figure 10. DWI lesion pattern and total lesion volume of APS-stroke and AF-stroke patients with a multi-territory lesion 72
Figure 11. Cumulative incidence curve for clinical outcomes according to secondary preventive antithrombotic drug category for aPL-stroke 73
Figure 12. Cumulative incidence curve for clinical outcomes according to dichotomized secondary preventive antithrombotic drug category for aPL-stroke 74
Figure 13. Hazard of composite outcome stratified by clinical factors 75